Advate vs Eloctate
Side-by-side cost comparison based on Medicare Part D data
Advate
Antihemophilic Factor (rDNA)
Manufactured by Takeda
Eloctate
Antihemophilic Factor (FC fusion)
Manufactured by Sanofi
Advate costs 20% less per claim than Eloctate ($25,333.00 vs $31,500.00). A generic version of Advate is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Advate | Eloctate |
|---|---|---|
| Avg Cost Per Claim | $25,333.00 | $31,500.00 |
| Total Medicare Spending | $456.0M | $567.0M |
| Total Beneficiaries | 2,100 | 2,100 |
| Total Claims | 18,000 | 18,000 |
| Annual Cost/Patient | $217,143.00 | $270,000.00 |
| Year-over-Year Change | -14.6% | -4.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Takeda | Sanofi |
| Condition | Blood Disorders | Blood Disorders |
| Generic Name | Antihemophilic Factor (rDNA) | Antihemophilic Factor (FC fusion) |
Advate vs Eloctate: What the Data Shows
Advate (Antihemophilic Factor (rDNA)) and Eloctate (Antihemophilic Factor (FC fusion)) are both used to treat blood disorders. Based on Medicare Part D data, Advate costs $25,333.00 per claim, which is 20% less than Eloctate at $31,500.00 per claim.
Medicare spent $456.0M on Advate and $567.0M on Eloctate. In terms of patient reach, Eloctate serves more beneficiaries (2,100 vs 2,100).
Year-over-year spending changed -14.6% for Advate and -4.6% for Eloctate.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Advate is cheaper at $25,333.00 per claim, compared to $31,500.00 for Eloctate. That makes Advate about 20% less expensive per claim based on Medicare Part D data.
Yes, both Advate and Eloctate are used to treat blood disorders. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Antihemophilic Factor (rDNA) and generic Antihemophilic Factor (FC fusion) can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $456.0M on Advate covering 2,100 beneficiaries, and $567.0M on Eloctate covering 2,100 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.